Literature DB >> 17963732

Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

Shinji Higashi1, Eizo Iseki, Ryoko Yamamoto, Michiko Minegishi, Hiroaki Hino, Koshiro Fujisawa, Takashi Togo, Omi Katsuse, Hirotake Uchikado, Yoshiko Furukawa, Kenji Kosaka, Heii Arai.   

Abstract

TAR-DNA-binding protein 43 (TDP-43) has been identified as a major component protein of ubiquitin-positive inclusions in brains from patients with frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis. To obtain the precise prevalence of TDP-43 pathology in neurodegenerative disorders, we examined brains from patients with tauopathies and synucleinopathies as well as FTLD-U using immunohistochemical analysis. Consequently, TDP-43-positive inclusions within neurons and oligodendroglia were found in brains from patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) in addition to FTLD-U, but not with Parkinson's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration or FTDP-17. The amygdala and hippocampus that were vulnerable to tau or alpha-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, in the frontal cortex and basal ganglia that were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed in AD and DLB cases. Thus, the neuroanatomical distribution of TDP-43 pathology in AD and DLB cases was obviously different from that in FTLD-U cases. Furthermore, a subset of TDP-43-positive inclusions co-existed with neurofibrillary tangles (NFTs) or Lewy bodies (LBs) in the same neurons. Upon double-immunofluorescent labeling analysis, TDP-43 was hardly superimposed with tau, while TDP-43 was partially superimposed with alpha-synuclein, suggesting that neither NFTs nor LBs themselves show TDP-43 immunoreactivity and that TDP-43 pathology found in this study may be related in some way to AD and LB pathology. This study will provide a more in-depth understanding of the various pathogenic pathways leading to neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963732     DOI: 10.1016/j.brainres.2007.09.048

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  162 in total

1.  Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A.

Authors:  Naoya Aoki; Melissa E Murray; Kotaro Ogaki; Shinsuke Fujioka; Nicola J Rutherford; Rosa Rademakers; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-11-04       Impact factor: 17.088

Review 2.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

3.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

Review 4.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

Review 5.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

Review 6.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

7.  Tau Interacts with the C-Terminal Region of α-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations.

Authors:  Anvesh K R Dasari; Rakez Kayed; Sungsool Wi; Kwang Hun Lim
Journal:  Biochemistry       Date:  2019-06-07       Impact factor: 3.162

8.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

9.  Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).

Authors:  Michaeline L Hebron; Irina Lonskaya; Kaydee Sharpe; Puwakdandawe P K Weerasinghe; Norah K Algarzae; Ashot R Shekoyan; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

Review 10.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.